UQ spin-off company to develop precision painkillers for treating debilitating conditions

Precision painkillers that are more accurate and less harmful to the liver are set to be developed by a University of Queensland spin-off company -; potentially changing the lives of millions of people.

Professor Trent Munro, from the Australian Institute for Bioengineering and Nanotechnology (AIBN), is the scientific co-founder of Cassowary Pharmaceuticals Pty Ltd which is creating a new range of hyper-targeted medications.

Professor Munro said the drugs would help treat debilitating and chronic pain conditions associated with cancer, sciatica, post-herpetic neuralgia (a painful condition that can follow shingles), peripheral nerve injury and osteoarthritis.

This type of targeted therapy reduces the potential side effects and safety issues associated with current pain treatments, and will also mean fewer doses are required. Creating drugs with these attributes could change the lives of millions of people who suffer from chronic neuropathic pain."

Professor Trent Munro, Australian Institute for Bioengineering and Nanotechnology

Professor Munro said up to 10 per cent of the adult population were affected by neuropathic pain, and current treatments often presented problems.

"Many existing treatments are ineffective in large numbers of patients, and carry significant risk of side-effects, including addiction," he said.

Cassowary Pharma's drug candidate targets a molecule thought to be important in how the human body senses pain.

"By building on the pioneering discoveries of Emeritus Professor Maree Smith, and using the critical tools developed in the laboratory of UQ's Professor Greg Monteith, we can create a drug that is very accurate, avoids the risk of liver toxicity, and lessens the overall medication load," Professor Munro said.

After receiving funding from the Medical Research Future Fund's (MRFF) national $40 million CUREator Scheme, Cassowary Pharma will be recruiting candidates for clinical trials over the next 18 months as it ramps up efforts to hit the market.

Professor Munro said shaping Cassowary Pharma's goals was a collaborative effort, involving Dr Lucia Zacchi of the School of Chemistry and Molecular Bioscience and AIBN's Dr Martina Jones.

It was one of four UQ start-ups to receive funding earlier this year, which are each working to find new treatments for a diverse range of hard-to-treat conditions.

UQ's commercialization company UniQuest CEO Dr Dean Moss congratulated Cassowary Pharma and said the funding recognized the leadership role that UQ plays in technology transfer and commercialization.

"I am always excited to acknowledge how innovative research excellence from UQ's institutes, faculties and schools is translated into real-world impact," Dr Moss said.

Comments

  1. ZaCloud StriFair ZaCloud StriFair United States says:

    Either the tags (& the image on the email newsletter that linked me here) are way out of line... Or this article just casually glossed over the fact that the "new medicine" is nanobots? And that by targeting the specific molecule it might involve actual bioengineering & change the makeup of people's bodies?? Uhhh, call it what it actually is, please. If the tags/image are correct, then this is WAY too important & revolutionary to be so casual & deceptively low-key about it. (Scary but exciting!)

    I sure hope the brave test subjects are at least informed about the nature of what they might receive (if not placebo or conventional medications). I know you don't want psychosomatic influence (though that's what the control groups are for), but for something this unprecedented (if, again, the unspoken details are accurate), they'd have the right to know, since that would be nothing like testing a new but still conventional treatment.

    (Especially if it also involves bioengineering & deletion of a molecule that isn't even fully understood... That could have a major domino effect if they're not careful. So again, that's something that I REALLY hope the testers are more open about with the volunteers than this article seems to be! Maaaaan...)

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post
You might also like...
What was the prevalence of adverse events following first and second dose COVID-19 vaccinations in England?